Human medicines European public assessment report (EPAR): Irbesartan Hydrochlorothiazide Zentiva (previously Irbesartan Hydrochlorothiazide Winthrop), irbesartan,hydrochlorothiazide, Date of authorisation: 18/01/2007, Revision: 37, Status: Authorised

Human medicines European public assessment report (EPAR): Xospata, gilteritinib, Date of authorisation: 24/10/2019, Revision: 8, Status: Authorised

Mysimba

Human medicines European public assessment report (EPAR): Terrosa, teriparatide, Date of authorisation: 04/01/2017, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Karvea, irbesartan, Date of authorisation: 26/08/1997, Revision: 49, Status: Authorised

Human medicines European public assessment report (EPAR): Tauvid, flortaucipir (18F), Date of authorisation: 22/08/2024, Revision: 2, Status: Authorised

Guidance for rapporteurs and members of drafting groups of documents developed by the GMP/GDP Inspectors Working Group

Human medicines European public assessment report (EPAR): Cyramza, ramucirumab, Date of authorisation: 19/12/2014, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Amyvid, florbetapir (18F), Date of authorisation: 14/01/2013, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Abiraterone Krka, abiraterone acetate, Date of authorisation: 24/06/2021, Revision: 5, Status: Authorised